Indeed, a cohort of NSCLC patients with both RASA1 and NF-1 mutations has been shown to be uniquely sensitive to MEK inhibitors [78, 88], and as our analysis found that mutated RASA1 results in increased ACOX2 (Fig. 4) this lends further support to the possibility that cancers overexpressing ACOX2 may also be sensitive to MEK inhibitors. The gene discussed is RASA1; the disease is non-small cell lung carcinoma.